102 Chapter 5 Dosing group 8 mg/kg (n=2212) Fixed dose tocilizumab (n=1196) Low dose tocilizumab 400mg (n=843) Sarilumab 400mg (n=1234) Patient characteristics Sex (%) Men 1394 (63.0) 741 (62.0) 552 (65.5) 812 (65.8) Women 818 (37.0) 455 (38.0) 291 (34.5) 422 (34.2) Age group, years (%) 18-29 18 (0.8) 25 (2.1) 7 (0.8) 12 (1.0) 30-39 61 (2.8) 79 (6.6) 31 (3.7) 51 (4.1) 40-49 172 (7.8) 152 (12.7) 56 (6.6) 81 (6.6) 50-59 524 (23.7) 238 (19.9) 126 (15.0) 206 (16.7) 60-69 653 (29.5) 261 (21.8) 198 (23.5) 294 (23.8) 70-79 628 (28.4) 273 (22.8) 277 (32.9) 363 (29.4) 80+ 156 (7.1) 168 (14.1) 148 (17.6) 227 (18.4) Charlson Comorbidity Index, median (IQR) 0.0 (0.0 to 1.0) 0.0 (0.0 to 1.0) 0.0 (0.0 to 2.0) 0.0 (0.0 to 2.0) Immunocompromised (%) 60 (2.7) 43 (3.6) 32 (3.8) 45 (3.7) Outcomes ICU admission (%) 1272 (57.5) 619 (51.8) 337 (40.0) 548 (44.4) ICU length of stay, median (IQR) 8.0 (4.0 to 17.0) 7.0 (4.0 to 15.0) 8.0 (3.0 to 14.0) 8.0 (4.0 to 15.0) Hospital length of stay, median (IQR) 13.0 (8.0 to 22.0) 12.0 (8.0 to 20.0) 11.0 (6.0 to 18.0) 11.0 (7.0 to 18.0) Location of death (%) Ward 305 (60.2) 233 (75.2) 197 (77.3) 308 (78.8) ICU 202 (39.8) 77 (24.8) 58 (22.8) 83 (21.2) Outcome (%) Death 507 (22.9) 310 (25.9) 255 (30.3) 391 (31.7) Alive 1563 (70.6) 722 (60.4) 478 (56.7) 705 (57.1) Missing 142 (6.4) 164 (13.7) 110 (13.1) 138 (11.2) Table 1: Characteristics and outcomes of patients treated with IL-6 inhibitors. IQR= Interquartile range. For definition of dosing groups: see methods section
RkJQdWJsaXNoZXIy MTk4NDMw